Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.

Murray L BarclayShwan KarimEsther T Johanna HelmsPaula E KeatingBarry D HockLisa K StampMichael Schultz

Published in: Internal medicine journal (2020)

Using the New Zealand ELISA assay, threshold concentrations of 5 mg/L for infliximab and 7 mg/L for adalimumab are suggested to aid dosing decisions, consistent with results internationally. Both neutralising (ELISA) and non-neutralising ADA (HMSA) are associated with low drug concentrations.

Keyphrases

ulcerative colitis
rheumatoid arthritis
high throughput
juvenile idiopathic arthritis
emergency department
adverse drug
hidradenitis suppurativa
monoclonal antibody